drugset / Trial / NCT00003018
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Chemotherapy following surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with stage II or stage III pancreatic cancer that has not been surgically removed.
Timeline
- Start
- 1997-09
- Primary completion
- 2002-01
- Completion
- 2007-01
Publications
- Results Isacoff WH, Bendetti JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA. Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol. 2007 May 1;25(13):1665-9. doi: 10.1200/JCO.2006.06.7637.
- Results Isacoff WH, Benedetti J, MacDonald JS, et al.: Continuous infusion (CI) 5 fluorouracil (5FU), leucovorin (LV), mitomycin C (Mito C) and dipyridamole (D) in patients with locally advanced unresectable pancreatic adenocarcinoma - a phase II trial of the Southwest Oncology Group. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-544, 2002.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dipyridamole | Other / unclassified | 75 mg | Oral |
| Subject | Leucovorin | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Mitomycin C | Other / unclassified | 10 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 200 mg/m2 | Intravenous |